Skye Bioscience (NASDAQ:SKYE – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20), Zacks reports.
Skye Bioscience Trading Up 1.8 %
NASDAQ:SKYE traded up $0.08 during trading hours on Monday, reaching $4.60. The company had a trading volume of 100,900 shares, compared to its average volume of 117,851. Skye Bioscience has a 52 week low of $1.44 and a 52 week high of $19.41. The company’s 50 day simple moving average is $5.81.
Analyst Ratings Changes
A number of brokerages have weighed in on SKYE. Cantor Fitzgerald restated an “overweight” rating and issued a $14.00 price objective on shares of Skye Bioscience in a report on Monday, July 1st. Craig Hallum initiated coverage on shares of Skye Bioscience in a research report on Tuesday, July 9th. They set a “buy” rating and a $18.00 price target for the company.
About Skye Bioscience
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Read More
- Five stocks we like better than Skye Bioscience
- How to Calculate Inflation Rate
- How to Invest in Silver: A Beginner’s Guide
- 3 Warren Buffett Stocks to Buy Now
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- The Risks of Owning Bonds
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
